First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

収録刊行物

被引用文献 (15)*注記

もっと見る

問題の指摘

ページトップへ